Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"INO's idea of using DNA, which is simple to make and cost-effective, to drive the body's natural immune response is just fascinating." (3/25/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jill Wahleithner More >
Ross Silver has been advising, researching and investing in public companies across all industries throughout his career. Prior to founding Vista Partners LLC in 2005, Silver served as a research analyst for a San Francisco-based hedge fund. From 2000 to 2003, Silver served as a research associate covering consumer discretionary and consumer staple companies at Dresdner RCM (now Allianz). Prior to joining Dresdner RCM, Silver was a member of CIBC's Technology, Media, and Telecom Investment Banking group, where he assisted with equity and debt offerings. Silver holds a bachelor's degree in business economics from the University of California, Santa Barbara. He has served as a consultant for government agencies including the National Institutes of Health (NIH). He holds a Series 65 Securities license.
Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy (12/6/12) Many components go into building a successful biotech company, but excellent management is a keystone. Combine good management with an innovative product or service, and investors can possibly unlock big multiples over their original investments. So says Principal Analyst and Fund Manager Ross Silver, co-founder of Vista Partners. In this interview with The Life Sciences Report, Silver brings obscure micro-cap ideas to life and discusses why they may have mammoth potential.
"We view Omidria sales as a means for OMER to fund one of the most exciting biotechnology pipelines in the industry." (4/8/15) Omeros Corp. - The Life Sciences Report Interview with Jason Kolbert More >
"STEM is doing pioneering work in the field of cervical spinal cord Injury and dry age-related macular degeneration." (4/8/15) StemCells Inc. - The Life Sciences Report Interview with Jason Kolbert More >